$NUVL just got swallowed for $10.6B — and now everyone's asking if $SJM is next on the acquisition menu

$NUVL is the ticker of the moment after GSK agreed to pay $10.6 billion — $124/share cash for the US biotech, a clean 40% premium. Reddit's biotech subs are equal parts celebrating and kicking themselves for not loading up sooner. YouTube finance channels are framing it as GSK desperately patching a hole left by expiring HIV drug patents, which is less romantic but probably more accurate. Two of the acquired drugs are in late-stage trials with FDA decisions expected this year — if either gets approved, GSK bought a bargain. If neither does, well, that's why GSK shares dropped ~2% on announcement day.

$SJM quietly beat Q4 earnings and popped 4.7%, which feels undeserved until you realize Cafe Bustelo is carrying the whole operation on its back while Dunkin' and Folgers volumes quietly decline. The gains are price-hike-driven, not volume-driven — which is either a sign of brand resilience or a warning that consumers are one recession away from switching to gas station coffee.

Meanwhile, OpenAI confidentially filed its S-1 with Goldman Sachs and Morgan Stanley at an ~$850 billion valuation — and social sentiment across X and YouTube is split between "generational wealth opportunity" and "please, we've been burned before." The hype is real, but so is the fact that we can't buy it yet, which is basically the most OpenAI thing imaginable.